UroGen Pharma Ltd (URGN) Stock Analysis

UroGen Pharma Ltd (URGN) is a publicly traded company in the HEALTHCARE sector. It trades at $26.54, carries a market capitalization of $1.32B. This page summarizes the public market data, fundamentals, and frequently asked questions for URGN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $26.54
• Market Cap: $1.32B
• EPS: $-2.74
• 52-Week High: $32.37
• 52-Week Low: $4.80

Market Sentiment

UroGen Pharma Ltd currently has a Bullish sentiment score of 0.27.

About UroGen Pharma Ltd

None

GNG Research Analysis

GNG Research scores UroGen Pharma Ltd (URGN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for URGN.

Frequently Asked Questions

Does URGN pay dividends?

UroGen Pharma Ltd (URGN) does not currently pay a regular dividend.

What is URGN's market cap?

UroGen Pharma Ltd (URGN) has a market capitalization of $1.32B with a current stock price of $26.54.